Deutsche Bank Aktiengesellschaft Begins Coverage on Inari Medical (NASDAQ:NARI)

Deutsche Bank Aktiengesellschaft began coverage on shares of Inari Medical (NASDAQ:NARI) in a research note issued to investors on Friday morning, Marketbeat.com reports. The firm issued a buy rating and a $68.00 price objective on the stock.

NARI has been the topic of several other research reports. William Blair assumed coverage on Inari Medical in a research report on Thursday, July 25th. They issued an outperform rating on the stock. Canaccord Genuity Group boosted their price target on Inari Medical from $55.00 to $71.00 and gave the company a buy rating in a research report on Wednesday, July 31st. Robert W. Baird dropped their price target on Inari Medical from $65.00 to $63.00 and set an outperform rating on the stock in a research report on Wednesday, July 31st. Piper Sandler dropped their price target on Inari Medical from $55.00 to $50.00 and set a neutral rating on the stock in a research report on Wednesday, May 1st. Finally, Truist Financial restated a hold rating and issued a $55.00 price target (down previously from $60.00) on shares of Inari Medical in a research report on Wednesday, July 31st. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of Moderate Buy and a consensus price target of $61.29.

Inari Medical Price Performance

Shares of NARI traded down $0.17 during midday trading on Friday, reaching $48.48. 27,528 shares of the stock were exchanged, compared to its average volume of 1,040,421. The company has a market capitalization of $2.82 billion, a price-to-earnings ratio of -118.66 and a beta of 1.01. Inari Medical has a twelve month low of $36.73 and a twelve month high of $71.85. The business’s 50-day moving average price is $49.87 and its 200 day moving average price is $48.21.

Insider Transactions at Inari Medical

In related news, CEO Andrew Hykes sold 3,000 shares of Inari Medical stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $50.00, for a total transaction of $150,000.00. Following the completion of the transaction, the chief executive officer now directly owns 465,474 shares in the company, valued at approximately $23,273,700. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director William Hoffman sold 40,000 shares of Inari Medical stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $46.60, for a total transaction of $1,864,000.00. Following the completion of the transaction, the director now directly owns 925,359 shares in the company, valued at approximately $43,121,729.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Andrew Hykes sold 3,000 shares of Inari Medical stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $50.00, for a total value of $150,000.00. Following the transaction, the chief executive officer now owns 465,474 shares of the company’s stock, valued at $23,273,700. The disclosure for this sale can be found here. Insiders have sold 216,744 shares of company stock valued at $11,218,680 in the last quarter. 10.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. BI Asset Management Fondsmaeglerselskab A S acquired a new position in Inari Medical in the 1st quarter valued at $30,000. GAMMA Investing LLC raised its holdings in Inari Medical by 164.7% in the 2nd quarter. GAMMA Investing LLC now owns 704 shares of the company’s stock valued at $34,000 after acquiring an additional 438 shares during the last quarter. Nisa Investment Advisors LLC raised its holdings in Inari Medical by 83.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 956 shares of the company’s stock valued at $46,000 after acquiring an additional 435 shares during the last quarter. Benjamin F. Edwards & Company Inc. increased its holdings in shares of Inari Medical by 27.4% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 1,098 shares of the company’s stock worth $71,000 after buying an additional 236 shares during the last quarter. Finally, Covestor Ltd increased its holdings in shares of Inari Medical by 30.2% during the 1st quarter. Covestor Ltd now owns 1,619 shares of the company’s stock worth $78,000 after buying an additional 376 shares during the last quarter. 90.98% of the stock is currently owned by institutional investors and hedge funds.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.